# Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis

> **NCT02601469** · PHASE2 · COMPLETED · sponsor: **Sun Pharmaceutical Industries, Inc.** · enrollment: 26 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** DSXS

## Key facts

- **NCT ID:** NCT02601469
- **Lead sponsor:** Sun Pharmaceutical Industries, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-04
- **Primary completion:** 2016-12-29
- **Final completion:** 2017-08-25
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2018-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02601469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02601469, "Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02601469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*